GlassScriptPhysician profile
Lisa K Quinn
NPI 1760740187
$14,948.41
in general payments reported to CMS, 2019-2025
65 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,088 · 2022: $3,091 · 2023: $2,522 · 2024: $3,924 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,297 · Travel and Lodging: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,296.82 |
| Travel and Lodging | $472.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,114.43 | 2021-2025 | |
| Ucb, INC. | $1,892.36 | 2021-2025 | Nayzilam, Briviact, Rystiggo |
| Livanova USA, INC. | $1,745.18 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $1,145.53 | 2021-2025 | Gocovri, Apokyn |
| Teva Pharmaceuticals USA, INC. | $680.57 | 2021-2025 | Ajovy, Austedo, Austedo Xr |
| Sk Life Science, INC. | $680.49 | 2021-2023 | |
| Lilly USA, LLC | $431.20 | 2021-2024 | Reyvow, Emgality, Amyvid |
| Biogen, INC. | $410.26 | 2021-2025 | Tysabri, Vumerity, Spinraza |
| Biohaven Pharmaceuticals, INC. | $387.67 | 2021 | |
| Neurelis, INC. | $379.33 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $359.70 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $325.05 | 2021-2025 | Ultomiris, Koselugo |
| Amgen INC. | $290.59 | 2021-2024 | Aimovig |
| Catalyst Pharmaceuticals, INC. | $283.19 | 2023-2025 | Fycompa, Firdapse |
| Lundbeck LLC | $272.77 | 2021-2025 | Vyepti |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.